NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $338.22 +1.85 (+0.55%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$336.32▼$340.4450-Day Range$267.72▼$338.2252-Week Range$208.62▼$343.98Volume290,257 shsAverage Volume492,505 shsMarket Capitalization$15.00 billionP/E Ratio15.99Dividend YieldN/APrice Target$330.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get United Therapeutics alerts: Email Address United Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside2.2% Downside$330.64 Price TargetShort InterestHealthy9.57% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.92Based on 32 Articles This WeekInsider TradingSelling Shares$30.47 M Sold Last QuarterProj. Earnings Growth9.85%From $24.87 to $27.32 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.64 out of 5 starsMedical Sector78th out of 936 stocksPharmaceutical Preparations Industry27th out of 436 stocks 2.4 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageUnited Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.57% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in United Therapeutics has recently decreased by 5.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 3.3 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 32 news articles for United Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 5 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows8 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,469,523.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 9.85% in the coming year, from $24.87 to $27.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 15.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.95.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 15.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.64.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 1.45. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. About United Therapeutics Stock (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesJuly 26 at 6:19 AM | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of StockJuly 24 at 5:20 AM | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 SharesJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 21, 2024 | marketbeat.comMeet some of the world's cleanest pigs, raised to grow kidneys and hearts for humansSome of the world's cleanest pigs are being raised in the Virginia mountains to supply kidneys and hearts for animal-to-human organ transplantsJuly 21, 2024 | marketbeat.comPig transplant research yields a surprise: Bacon safe for some people allergic to red meatSome people develop a weird allergy to red meat after being bitten by a lone star tick yet find they can still eat pork from a surprising source - certain pigs originally bred for human organ transplantsJuly 18, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,180,908.00 in StockJuly 16, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,169,892.00 in StockJuly 10, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,127,700.00 in StockJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.June 28, 2024 | insidertrades.comNilda Mesa Sells 266 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockJuly 26 at 7:34 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Price Target Raised to $400.00 at HC WainwrightJuly 26 at 6:52 AM | investorplace.comThe 3 Best 3D Bioprinting Stocks to Buy NowJuly 26 at 1:50 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Sets New 12-Month High on Analyst UpgradeJuly 25 at 1:19 PM | markets.businessinsider.comNavigating 9 Analyst Ratings For United TherapeuticsJuly 25 at 5:08 AM | americanbankingnews.comMartine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockJuly 22, 2024 | finance.yahoo.comIs Now The Time To Put United Therapeutics (NASDAQ:UTHR) On Your Watchlist?July 22, 2024 | benzinga.comHere's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth TodayJuly 20, 2024 | msn.comIf You Invested $1000 in United Therapeutics a Decade Ago, This is How Much It'd Be Worth NowSee More Headlines Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$330.64 High Stock Price Target$400.00 Low Stock Price Target$240.00 Potential Upside/Downside-2.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$21.15 Trailing P/E Ratio15.99 Forward P/E Ratio13.60 P/E Growth1.45Net Income$984.80 million Net Margins42.05% Pretax Margin55.28% Return on Equity18.72% Return on Assets15.35% Debt Debt-to-Equity Ratio0.04 Current Ratio3.77 Quick Ratio3.64 Sales & Book Value Annual Sales$2.33 billion Price / Sales6.45 Cash Flow$22.53 per share Price / Cash Flow15.01 Book Value$127.35 per share Price / Book2.66Miscellaneous Outstanding Shares44,360,000Free Float38,812,000Market Cap$15.00 billion OptionableOptionable Beta0.55 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 69)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 52)President & COO Comp: $2.83MMr. James C. Edgemond (Age 56)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 60)Executive VP, General Counsel & Corporate Secretary Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate Vice President of Human ResourcesKevin T. GraySenior Vice President of Strategic Operations & LogisticsMr. Patrick Poisson (Age 56)Executive VP of Technical Operations Dr. Leigh PetersonExecutive Vice President of Product Development & XenotransplantationMr. Gil GoldenSenior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsTeva Pharmaceutical IndustriesNYSE:TEVABlueprint MedicinesNASDAQ:BPMCReata PharmaceuticalsNASDAQ:RETABridgeBio PharmaNASDAQ:BBIOPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 23,494 shares on 7/26/2024Ownership: 0.980%AustralianSuper Pty LtdBought 25,031 shares on 7/26/2024Ownership: 0.056%AlphaCentric Advisors LLCSold 1,500 shares on 7/26/2024Ownership: 0.033%State of Michigan Retirement SystemBought 500 shares on 7/26/2024Ownership: 0.029%Access Investment Management LLCBought 55 shares on 7/26/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $219.89 at the beginning of the year. Since then, UTHR shares have increased by 53.8% and is now trading at $338.22. View the best growth stocks for 2024 here. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) issued its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. The company's revenue was up 33.7% on a year-over-year basis. What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. Who are United Therapeutics' major shareholders? United Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.98%), Swedbank AB (0.95%), Allspring Global Investments Holdings LLC (0.62%) and Retirement Systems of Alabama (0.32%). Insiders that own company stock include Paul A Mahon, Louis W Sullivan, Judy D Olian, Nilda Mesa, Christopher Causey, Martine A Rothblatt, Raymond Dwek and Christopher Patusky. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE) and Johnson & Johnson (JNJ). This page (NASDAQ:UTHR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
